Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoledronic acid - Novartis

Next Previous
Drug Profile

Zoledronic acid - Novartis

Alternative Names: Aclasta; AK-156; CGP-42446A; Reclast; ZOL-446; zoledronate; Zometa

Latest Information Update: 22 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Asahi Kasei Pharma Corp; Novartis; UNICANCER
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone metastases; Corticosteroid-induced osteoporosis; Fracture; Male osteoporosis; Malignant hypercalcaemia; Mesothelioma; Multiple myeloma; Osteitis deformans; Postmenopausal osteoporosis
  • Registered Osteoporosis
  • Phase II Breast cancer
  • Discontinued Osteogenesis imperfecta; Osteosarcoma; Rheumatoid arthritis

Most Recent Events

  • 22 Nov 2024 No development reported - Phase-III for Osteoporosis (In the elderly) in Germany (IV)
  • 22 Nov 2024 No development reported - Phase-III for Osteoporosis (In the elderly) in USA (IV)
  • 25 May 2021 Novartis and University of Sheffield completes the phase III AZURE trial in Breast cancer (Adjuvant therapy) in USA, Spain, Australia, Ireland, Portugal, Taiwan, Thailand and the United Kingdom, before May 2021 (ISRCTN79831382) (NCT00072020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top